Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats

References

• Nimmerfall F, Rosenthaler J. (1980). Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. J Pharm Sci, 69:605–607.
   PubMed Web of Science ®Google Scholar
• Shastri S, Mroszczak E, Prichard RK, Parekh P, Nguyen TH, Hennessey DR et al. (1980). Relationship among particle size distribution, dissolution profile, plasma values, and anthelmintic efficacy of oxfendazole. Am J Vet Res, 41:2095–2101.
   PubMed Web of Science ®Google Scholar
• Englund DE, Johansson ED. (1981). Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particles sizes. Ups J Med Sci, 86:297–307.
   PubMed Web of Science ®Google Scholar
• Watari N, Funaki T, Aizawa K, Kaneniwa N. (1983). Nonlinear assessment of nitrofurantoin bioavailability in rabbits. J Pharmacokinet Biopharm, 11:529–545.
   PubMedGoogle Scholar
• Hargrove JT, Maxson WS, Wentz AC. (1989). Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol, 161:948–951.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Stella VJ, Rajewski RA. (1997). Cyclodextrins: their future in drug formulation and delivery. Pharm Res, 14:556–567.
   PubMed Web of Science ®Google Scholar
• Floyd AG. (1999). Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today, 4:134–143.
   PubMedGoogle Scholar
• Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89–121.
   PubMed Web of Science ®Google Scholar
• Nakano M. (2000). Places of emulsions in drug delivery. Adv Drug Deliv Rev, 45:1–4.
   PubMed Web of Science ®Google Scholar
• Akers MJ. (2002). Excipient-drug interactions in parenteral formulations. J Pharm Sci, 91:2283–2300.
   PubMed Web of Science ®Google Scholar
• Weiner M, Bernstein IL. (1989). Adverse ractions to drug formulation agents. New York: Marcel Dekker.
   Google Scholar
• Gad SC. (2002). Drug safety evaluation. Ch. 13.8. New York: John Wiley and Sons.
   Google Scholar
• Gassman P, List M, Scheitzer A, Sucker H. (1994). Hydrosols – alternatives for the parenteral application of poorly water soluble drugs. Eur J Biopharm, 40:64–72.
   Web of Science ®Google Scholar
• Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–97.
   Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–313.
   Web of Science ®Google Scholar
• Müller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by size-reduction technique. Int J Pharm, 160:229–237.
   Web of Science ®Google Scholar
• Jia L, Wong H, Cerna C, Weitman SD. (2002). Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091–1096.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113–120.
   PubMed Web of Science ®Google Scholar
• Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22:906–910.
   PubMed Web of Science ®Google Scholar
• Lindfors L, Forssén S, Skantze P, Skantze U, Zackrisson A, Olsson U. (2006). Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations. Langmuir, 22:911–916.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2009). Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm, 35:1479–1486.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res, 19:921–925.
   PubMed Web of Science ®Google Scholar
• Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57:273–285.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2011). Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm, 37:243–251.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Björkman JA, Skantze P, Zachrisson H. (2011). Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound. J Pharm Sci, 100:2194–2202.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. (2002). Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci, 16:53–61.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Müller RH. (2002). Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res, 19:189–194.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lv H, Jiang K, Gao Y. (2011). Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm, 420:180–188.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. (2012). Subcutaneous administration of nano- and microsuspenions can modify the release of poorly soluble compounds in rats. Submitted.
   Google Scholar
• Mitri K, Shegokar R, Gohla S, Anselmi C, Müller RH. (2011). Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm, 420:141–146.
   PubMed Web of Science ®Google Scholar
• Ploj K, Albery-Larsdotter S, Arlbrandt S, Kjaer MB, Skantze P, Storlien LH. (2010). The metabotropic glutamate mGluR5 receptor agonist CHPG stimulates food intake. Neuroreport 21:701–708.
   Google Scholar
• Sundqvist M, Kristensson E, Adolfsson R, Leffler A, Ahlstedt I, Engberg S et al. (2007). Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists. Eur J Pharmacol, 577:78–86.
   PubMed Web of Science ®Google Scholar
• Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017–1022.
   Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Bosselmann S, Williams RO. (2012). Has nanotechnology led to improved therapeutic outcomes? Drug Dev Ind Pharm, 38:158–170.
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. (1997). Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res, 14:1479–1484.
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. (2001). Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev, 50:143–156.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman SA. (2000). Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci, 89:297–310.
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Porter CJ. (2011). Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev, 63:890–900.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist A, Strimfors M. (2011). Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor–the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm, 37:1036–1042.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Nordmark A, Theilig S, Lindahl A. (2011). A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev Ind Pharm, 37:185–192.
   PubMed Web of Science ®Google Scholar
• Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK et al. (2002). Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res, 62:6831–6836.
   PubMed Web of Science ®Google Scholar
• Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. (2000). Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer, 82:1513–1518.
   PubMed Web of Science ®Google Scholar
• Lieleg O, Baumgärtel RM, Bausch AR. (2009). Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J, 97:1569–1577.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Poh MZ, Insin N, Bawendi MG, Fukumura D, Munn LL et al. (2010). Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J, 99:1342–1349.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy SL, Lee JK, Mintz Y, Cullen J, Savu MK, Easter DW et al. (2010). The impact of proton-pump inhibitors on intraperitoneal sepsis: a word of caution for transgastric NOTES procedures. Surg Endosc, 24:16–20.
   PubMed Web of Science ®Google Scholar
• Hanly EJ, Aurora AA, Shih SP, Fuentes JM, Marohn MR, De Maio A et al. (2007). Peritoneal acidosis mediates immunoprotection in laparoscopic surgery. Surgery, 142:357–364.
   PubMed Web of Science ®Google Scholar